Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. more
Time Frame | SABS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 13.97% | -2.12% | -3% |
1-Month Return | 51.96% | -3.42% | -0.73% |
3-Month Return | 37.17% | -11.13% | 2.87% |
6-Month Return | 67.87% | -5.74% | 7.17% |
1-Year Return | -38% | 3.97% | 25.31% |
3-Year Return | -94.59% | 1.05% | 28.38% |
5-Year Return | -95.42% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 3.44M | 55.24M | 60.88M | 23.90M | 2.24M | [{"date":"2019-12-31","value":5.65,"profit":true},{"date":"2020-12-31","value":90.74,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":39.27,"profit":true},{"date":"2023-12-31","value":3.68,"profit":true}] |
Cost of Revenue | - | - | 1.65M | 3.29M | 3.75M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":44.15,"profit":true},{"date":"2022-12-31","value":87.89,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 3.44M | 55.24M | 59.22M | 20.61M | (1.51M) | [{"date":"2019-12-31","value":5.81,"profit":true},{"date":"2020-12-31","value":93.27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":34.8,"profit":true},{"date":"2023-12-31","value":-2.54,"profit":false}] |
Gross Margin | 100.00% | 100.00% | 97.28% | 86.23% | (67.28%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.28,"profit":true},{"date":"2022-12-31","value":86.23,"profit":true},{"date":"2023-12-31","value":-67.28,"profit":false}] |
Operating Expenses | 12.12M | 34.68M | 13.39M | 28.92M | 40.31M | [{"date":"2019-12-31","value":30.05,"profit":true},{"date":"2020-12-31","value":86.03,"profit":true},{"date":"2021-12-31","value":33.22,"profit":true},{"date":"2022-12-31","value":71.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (8.67M) | 20.56M | (13.39M) | (28.92M) | (38.08M) | [{"date":"2019-12-31","value":-42.19,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-65.15,"profit":false},{"date":"2022-12-31","value":-140.67,"profit":false},{"date":"2023-12-31","value":-185.22,"profit":false}] |
Total Non-Operating Income/Expense | (628.09K) | (882.04K) | (4.02M) | 9.97M | (4.31M) | [{"date":"2019-12-31","value":-6.3,"profit":false},{"date":"2020-12-31","value":-8.85,"profit":false},{"date":"2021-12-31","value":-40.34,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-43.25,"profit":false}] |
Pre-Tax Income | (8.99M) | 20.12M | (17.14M) | (18.72M) | (42.19M) | [{"date":"2019-12-31","value":-44.67,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-85.22,"profit":false},{"date":"2022-12-31","value":-93.03,"profit":false},{"date":"2023-12-31","value":-209.73,"profit":false}] |
Income Taxes | 431.07K | 473.15K | 299.95K | 25.63K | (2.00) | [{"date":"2019-12-31","value":91.11,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":63.39,"profit":true},{"date":"2022-12-31","value":5.42,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (9.42M) | 19.64M | (17.44M) | (18.74M) | (42.19M) | [{"date":"2019-12-31","value":-47.94,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-88.8,"profit":false},{"date":"2022-12-31","value":-95.4,"profit":false},{"date":"2023-12-31","value":-214.79,"profit":false}] |
Income From Continuous Operations | (8.99M) | 20.12M | (17.14M) | (18.74M) | (27.21M) | [{"date":"2019-12-31","value":-44.67,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-85.22,"profit":false},{"date":"2022-12-31","value":-93.16,"profit":false},{"date":"2023-12-31","value":-135.26,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (9.42M) | 20.12M | (17.44M) | (18.74M) | (42.19M) | [{"date":"2019-12-31","value":-46.81,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-86.71,"profit":false},{"date":"2022-12-31","value":-93.16,"profit":false},{"date":"2023-12-31","value":-209.73,"profit":false}] |
EPS (Diluted) | - | - | 0.13 | (0.41) | (3.77) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-315.38,"profit":false},{"date":"2023-12-31","value":-2900,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SABS | |
---|---|
Cash Ratio | 3.45 |
Current Ratio | 3.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SABS | |
---|---|
ROA (LTM) | -78.80% |
ROE (LTM) | -174.73% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SABS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.31 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.69 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SABS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 23.79 |
P/B | 0.98 |
Price/FCF | NM |
EV/R | 1.21 |
EV/Ebitda | NM |
SAB Biotherapeutics Inc (SABS) share price today is $4.65
Yes, Indians can buy shares of SAB Biotherapeutics Inc (SABS) on Vested. To buy SAB Biotherapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SABS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of SAB Biotherapeutics Inc (SABS) via the Vested app. You can start investing in SAB Biotherapeutics Inc (SABS) with a minimum investment of $1.
You can invest in shares of SAB Biotherapeutics Inc (SABS) via Vested in three simple steps:
The 52-week high price of SAB Biotherapeutics Inc (SABS) is $7.52. The 52-week low price of SAB Biotherapeutics Inc (SABS) is $2.16.
The price-to-earnings (P/E) ratio of SAB Biotherapeutics Inc (SABS) is
The price-to-book (P/B) ratio of SAB Biotherapeutics Inc (SABS) is 0.98
The dividend yield of SAB Biotherapeutics Inc (SABS) is 0.00%
The market capitalization of SAB Biotherapeutics Inc (SABS) is $35.99M
The stock symbol (or ticker) of SAB Biotherapeutics Inc is SABS